Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ketamine infusion tested against unrelenting cancer pain

NCT ID NCT03362073

Symptom relief Sponsor: Pusan National University Yangsan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers are testing whether a continuous intravenous infusion of ketamine can ease severe cancer pain that no longer responds to standard opioid painkillers. The trial enrolls terminally ill cancer patients whose pain remains uncontrolled despite high doses of morphine-like drugs. Participants receive a steadily increasing dose of ketamine through an IV over five days, and researchers track changes in pain intensity and the need for rescue pain medication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ketamine given as a continuous intravenous infusion
What this could lead to
If it works, continuous ketamine infusion could become an option for cancer patients whose severe pain no longer responds to standard opioid treatment.
What could go wrong
This is a small Phase II trial with 20 participants, so any benefit may not hold in larger groups. Ketamine can cause sedation, confusion, or hallucinations, and it may not relieve pain for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

20 people

The number who actually took part.

Started

Jun 2018

Finished

Jan 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Among patients with histologically or cytologically confirmed malignancy, patients with expected survival time of several months or less due to a progressive disease without additional anticancer treatment. 2. Patients with refractory cancer pain, which cases of requesting 4 or more breakthrough analgesics or increase of baseline analgesics (average pain score ≥ 4 or Personalized pain goal) in spite of 120 mg/day or more of intravenous Morphine Equivalent Daily Dose 3. Hospitalized patients with intravascular access during at least 5 days 4. Age 18 or older 5. Signed and dated informed consent of document indicating that the patient (or legally acceptable representative) has been informed about all pertinent aspects of the trial prior to enrollment Exclusion Criteria: 1. Patients who were treated with ketamine for pain control within 6 months 2. Patients who have been treated with radiotherapy within 4 weeks or plan to intervention for pain control during study period 3. Cancer pain cannot be excluded the Opioid induced hyperalgesia 4. Concomitant severe medical, surgical, or disease or problems which were contraindicated to application of Ketamine or have possibilities of unexpected medical problems caused be the Ketamine * confirmed or assumed central nervous system lesion which lead to increased intracranial pressure * Arrhythmia (supra-ventricular tachycardia, ventricular arrhythmia (frequent premature ventricular contraction, bigeminy, Ventricular tachycardia) * history of hemorrhagic stroke or seizure within 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ketamine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cancer Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ketamine Refractory cancer pain

Contacts and locations

Locations

  • Pusan National University Yangsan Hospital

    Yangsan, Gyeongsangnam-do, 50612, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.